GeorgeWSledgeJr.MD

Oncology • Palo Alto, CA

Professor of Medicine, Indiana University

Join to view full profile

Dr. Sledge is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sledge's full profile

Already have an account?

Office
900 Blake Wilbur Dr
Palo Alto, CA 94304
Phone+1 650-498-6004

Fax+1 650-498-5840
Is this information wrong?

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1981 - 1983
St Louis University School of MedicineResidency, Internal Medicine, 1977 - 1980
Tulane University School of MedicineClass of 1977

Certifications & Licensure

CA State Medical License 2013 - 2024
IN State Medical License 1983 - 2013
LA State Medical License 1977 - 1983
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2 Start of enrollment: 1999 Aug 01
Completed
Phase 2
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer Start of enrollment: 2003 Jun 06
Completed
Phase 3
A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer Start of enrollment: 2005 Sep 01
Terminated
Quality of Life in Female Breast Cancer Survivors and Their Spouse, Partner, or Acquaintance Start of enrollment: 2006 Apr 03
Completed
Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer Start of enrollment: 2006 Oct 01
Completed
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer Start of enrollment: 2007 Sep 01
Terminated
Lonafarnib in Metastatic Breast Cancer Start of enrollment: 2008 Oct 01
Terminated
Phase 2
Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer Start of enrollment: 2009 Aug 01
Terminated
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer Start of enrollment: 2017 Oct 30
Completed
Phase 1
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer Start of enrollment: 2020 Oct 13
Terminated
Phase 1
Join now to see all

Publications & Presentations

PubMed

8 citations
Breast Cancer Diagnosis, Treatment, and Outcomes of Patients From Sex and Gender Minority Groups.
Erik Eckhert, Olivia Lansinger, Victor Ritter, Mina Liu, Summer Han, Lidia Schapira, Esther M John, Scarlett Gomez, George Sledge, Allison W Kurian> ;JAMA Oncology. 2023 Apr 1
2 citations
Reply to B. Ulaş Kahya et al and A. Soran et al.
Seema Ahsan Khan, Fengmin Zhao, Lori Goldstein, Joseph Sparano, George Sledge> ;Journal of Clinical Oncology. 2022 Nov 20
2 citations
Incident comorbidities after tamoxifen or aromatase inhibitor therapy in a racially and ethnically diverse cohort of women with breast cancer.
Tanya Gupta, Natasha Purington, Mina Liu, Summer Han, George Sledge, Lidia Schapira, Allison W Kurian> ;Breast Cancer Research and Treatment. 2022 Nov 1
1 citations
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Masakazu Toi, Chiun-Sheng Huang, Young-Hyuck Im, Joohyuk Sohn, Wei Zhang, Sachi Sakaguchi, Nadine Haddad, Gertjan van Hal, George W Sledge Jr> ;Cancer Science. 2023 Jan 1
Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.
Divya A Parikh, Lisa Kody, Susie Brain, Diane Heditsian, Vivian Lee, Christina Curtis, Mardi R Karin, Irene L Wapnir, Manali I Patel, George W Sledge Jr, Jennifer L Ca...> ;Breast Cancer Research and Treatment. 2022 Jul 1
4 citations
Impact of African ancestry on the relationship between body mass index and survival in an early-stage breast cancer trial (ECOG-ACRIN E5103).
Tarah J Ballinger, Guanglong Jiang, Fei Shen, Kathy D Miller, George W Sledge Jr, Bryan P Schneider> ;Cancer. 2022 Jun 1
32 citations
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Sara M Tolaney, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Eva-Maria Grischke, Antonio Llombart-Cussac, Hatem Soliman, Hong Wang, Sameera Wijayawardana, Valerie M Jans...> ;Clinical Cancer Research. 2022 Apr 14
24 citations
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation...
Gelareh Sadigh, Robert J Gray, Joseph A Sparano, Betina Yanez, Sofia F Garcia, Lava R Timsina, Samilia Obeng-Gyasi, Ilana Gareen, George W Sledge, Timothy J Whelan, Da...> ;JAMA Oncology. 2022 Apr 1
64 citations
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
Seema A Khan, Fengmin Zhao, Lori J Goldstein, David Cella, Mark Basik, Mehra Golshan, Thomas B Julian, Barbara A Pockaj, Christine A Lee, Wajeeha Razaq, Joseph A Spara...> ;Journal of Clinical Oncology. 2022 Mar 20
10 citations
Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer.
Joseph A Sparano, Anne O'Neill, Noah Graham, Donald W Northfelt, Chau T Dang, Antonio C Wolff, George W Sledge, Kathy D Miller> ;NPJ Breast Cancer. 2022 Feb 8
3 citations
Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported ou...
Sofia F. Garcia, Robert Gray, Joseph A. Sparano, Amye J. Tevaarwerk, Ruth C. Carlos, Betina Yanez, Ilana F. Gareen, Timothy J. Whelan, George W. Sledge, David Cella, L...> ;Cancer. 2021 Oct 6
3 citations
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer
Patrick Neven, Stephen R. D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh,...> ;Clinical Cancer Research. 2021 Nov 1
3 citations
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.
Michael S. Gordon, John Nemunaitis, Minal A. Barve, Zev A. Wainberg, Erika Hamilton, Ramesh K. Ramanathan, George W. Sledge, Huibin Yue, Susan E. Morgan-Lappe, Martha ...> ;Molecular Cancer Therapeutics. 2021 Jul 26
19 citations
Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial.
Gelareh Sadigh, Robert Gray, Joseph A. Sparano, Betina Yanez, Sofia F. Garcia, Lava Timsina, George W. Sledge, David Cella, Lynne I. Wagner, Ruth C. Carlos> ;Cancer. 2021 Jul 15
12 citations
Association of Modifiable Risk Factors with Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial
Betina Yanez, Robert Gray, Joseph A. Sparano, Ruth C. Carlos, Gelareh Sadigh, Sofia F. Garcia, Ilana F. Gareen, Timothy J. Whelan, George W. Sledge, David Cella, Lynne...> ;JAMA Oncology. 2021 Jun 17
15 citations
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup an...
Patrick Neven, Hope S. Rugo, Sara M. Tolaney, Hiroji Iwata, Masakazu Toi, Matthew P. Goetz, Peter A. Kaufman, Yi Lu, Nadine Haddad, Karla Hurt, George W. Sledge> ;Breast Cancer Research. 2021 Jun 11
The optimal duration of endocrine therapy in hormone receptor-positive breast cancer.
George W. Sledge> ;Clinical Advances in Hematology & Oncology. 2021 Jun 1
3 citations
Treatment and Monitoring Variability in US Metastatic Breast Cancer Care.
Jennifer L. Caswell-Jin, Alison Callahan, Natasha Purington, Summer S. Han, Haruka Itakura, Esther M. John, Douglas W. Blayney, George W. Sledge, Nigam H. Shah, Alliso...> ;JCO Clinical Cancer Informatics. 2021 May 27
11 citations
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor r...
Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Masato Takahashi, Yoshinori Ito, Yasuo Miyoshi, Takahiro Nakayama, Hirofumi Mukai, Jan-Stefan van der Walt, Joji Mori, Sa...> ;Breast Cancer. 2021 Apr 1
17 citations
Y box binding protein 1 inhibition as a targeted therapy for ovarian cancer
Dhanir Tailor, Angel Resendez, Fernando García-Marqués, Mallesh Pandrala, Catherine C. Going, Abel Bermudez, Vineet Kumar, Marjan Rafat, Dhanya Nambiar, Alexander Honk...> ;Cell Chemical Biology. 2021 Aug 19
11 citations
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2‐ advanced breast cancer: MONARCH 2 & 3 trials
Masakazu Toi, Kenichi Inoue, Norikazu Masuda, Hiroji Iwata, Joohyuk Sohn, In Hae Park, Seock-Ah Im, Shin-Cheh Chen, Sotaro Enatsu, P. Kellie Turner, Valerie Andre, Mol...> ;Cancer Science. 2021 Mar 8
510 citations
Liquid biopsy enters the clinic - implementation issues and future challenges.
Michail Ignatiadis, George W. Sledge, Stefanie S. Jeffrey> ;Nature Reviews. Clinical Oncology. 2021 Jan 20
19 citations
Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced b...
Matthew P. Goetz, Meena Okera, Hans Wildiers, Mario Campone, EM Grischke, Luis Manso, Valerie Andre, Nadia Chouaki, Belen San Antonio, Masakazu Toi, George W. Sledge> ;Breast Cancer Research and Treatment. 2021 Jan 3
10 citations
Impact of insurance and neighborhood socioeconomic status on clinical outcomes in therapeutic clinical trials for breast cancer
Samilia Obeng-Gyasi, Anne O'Neill, Fengmin Zhao, Sheetal Mehta Kircher, Timisina R. Lava, Lynne I. Wagner, Kathy D. Miller, Joseph A. Sparano, George W. Sledge, Ruth C...> ;Cancer Medicine. 2021 Jan 1
498 citations
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, M S Aapro, F André, C H Barrios, J Bergh, G S Bhattacharyya, L Biganzoli, F Boyle, M-J Cardoso, L A Carey, J Cortés...> ;Annals of Oncology. 2020 Dec 1
Join now to see all

Lectures

The 15th International Symposium on Anti-Angiogenic Therapy: Recent Advances and Future Directions in Basic and Clinical Care Research
The University of Texas, M. D. Anderson Cancer Center, San Diego, California - 1/31/2013

Press Mentions

ImmixBio Announces Dr. George W. Sledge of Stanford University Medical Center Joins Scientific Advisory BoardAugust 9th, 2021
Susan G. Komen® Announces 30 New Grants to Advance Discovery in Critical and Emerging Areas of Breast Cancer ResearchJune 30th, 2021
Susan G. Komen® Announces $1.2 Million in New Grants to 3 Vanderbilt University Medical Center ResearchersJune 30th, 2021
Join now to see all